AUSTIN, Texas, Jan. 4, 2021 /PRNewswire/ -- Aeglea
BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology
company developing a new generation of human enzyme therapeutics to
benefit people with rare metabolic diseases, today announced it
will present at the 39th Annual J.P. Morgan Healthcare
Conference being held virtually January
11-14.
Presentation Details
Date: Wednesday, January 13
Time: 8:20 a.m. EST
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's
president and chief executive officer
Webcast:
https://ir.aeglea.com/events-and-presentations/
To access the live and archived webcasts, visit the Events &
Presentations section of the Company's website. Please connect to
the website at least 15 minutes prior to the presentation to allow
for any software download that may be necessary. A replay of the
webcast will be available through the Company's website for 30 days
thereafter.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a late clinical-stage biotechnology
company redefining the potential of human enzyme therapeutics to
benefit people with rare and devastating metabolic diseases with
limited treatment options. Aeglea's lead product candidate,
pegzilarginase, is in a pivotal Phase 3 trial for the treatment of
Arginase 1 Deficiency and has received both Rare Pediatric Disease
and Breakthrough Therapy Designation. In the second quarter of
2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177
for the treatment of Homocystinuria. AGLE-177 has also been granted
Rare Pediatric Disease Designation. Aeglea has an active discovery
platform focused on engineering small changes in human enzymes to
have big impact on the lives of patients and their families. For
more information, please visit http://aeglea.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-present-at-39th-annual-jp-morgan-healthcare-conference-301200439.html
SOURCE Aeglea BioTherapeutics, Inc.